Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,939,839
  • Shares Outstanding, K 156,818
  • Annual Sales, $ 346,640 K
  • Annual Income, $ -282,370 K
  • 60-Month Beta 1.91
  • Price/Sales 4.44
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.22
  • Number of Estimates 4
  • High Estimate 0.26
  • Low Estimate 0.19
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +1,200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.22 +1.27%
on 01/24/20
14.10 -12.27%
on 12/26/19
-1.63 (-11.64%)
since 12/24/19
3-Month
9.00 +37.44%
on 10/25/19
14.10 -12.27%
on 12/26/19
+3.32 (+36.69%)
since 10/24/19
52-Week
7.91 +56.38%
on 10/02/19
15.21 -18.67%
on 02/15/19
-0.12 (-0.96%)
since 01/24/19

Most Recent Stories

More News
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS(R) (linaclotide) Patent Litigation

--- The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 -

IRWD : 12.37 (-3.59%)
AGN : 188.19 (-1.26%)
Gastro Esophageal Reflux Disease Drug and Devices Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 49.28 (-1.83%)
BSX : 43.21 (-0.83%)
CEMP : 2.33 (+1.30%)
STIM : 4.19 (-1.87%)
GSK : 47.23 (-1.23%)
IRWD : 12.37 (-3.59%)
MDGS : 1.87 (unch)
MDT : 119.26 (-1.41%)
MRK : 85.98 (-2.91%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Ironwood Pharmac Shares Up 37.3% Since SmarTrend's Buy Recommendation (IRWD)

SmarTrend identified an Uptrend for Ironwood Pharmac (NASDAQ:IRWD) on October 28th, 2019 at $9.32. In approximately 3 months, Ironwood Pharmac has returned 37.34% as of today's recent price of $12.80....

IRWD : 12.37 (-3.59%)
Uptrend Call Working As Ironwood Pharmac Stock Rises 38.9% (IRWD)

SmarTrend identified an Uptrend for Ironwood Pharmac (NASDAQ:IRWD) on October 28th, 2019 at $9.32. In approximately 3 months, Ironwood Pharmac has returned 38.95% as of today's recent price of $12.95....

IRWD : 12.37 (-3.59%)
Look for Shares of Ironwood Pharmac to Potentially Rebound after Yesterday's 1.61% Sell Off

Ironwood Pharmac (NASDAQ:IRWD) traded in a range yesterday that spanned from a low of $12.80 to a high of $13.10. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of...

IRWD : 12.37 (-3.59%)
50.3% Return Seen to Date on SmarTrend Ironwood Pharmac Call (IRWD)

SmarTrend identified an Uptrend for Ironwood Pharmac (NASDAQ:IRWD) on October 28th, 2019 at $9.32. In approximately 2 months, Ironwood Pharmac has returned 50.32% as of today's recent price of $14.01....

IRWD : 12.37 (-3.59%)
Dynavax Technolo is Among the Companies in the Biotechnology Industry with the Best Relative Performance (DVAX , VRTX , IRWD , EXEL , SAGE )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

DVAX : 5.78 (+0.70%)
IRWD : 12.37 (-3.59%)
VRTX : 229.06 (-2.07%)
Ironwood and Allergan Announce Settlement Resolving LINZESS(R) (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in...

IRWD : 12.37 (-3.59%)
AGN : 188.19 (-1.26%)
Constipation Treatment Drug Market Progression Factors, Industry Analysis And Forecast By 2024

The Global Constipation Treatment Drug Market report has been compiled by the best subject matter experts and market research professionals to ensure that the data in the report is obtained from the most...

ABT : 90.40 (-0.36%)
ALBO : 23.15 (-2.11%)
BAYRY : 20.8000 (-3.66%)
IRWD : 12.37 (-3.59%)
PBH : 40.88 (-1.78%)
SCMP : 18.05 (+0.28%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 4:00 p.m. Pacific Time/ 7:00 p.m. Eastern...

JPM : 133.15 (-2.48%)
IRWD : 12.37 (-3.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IRWD with:

Business Summary

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome...

See More

Key Turning Points

2nd Resistance Point 13.29
1st Resistance Point 12.83
Last Price 12.37
1st Support Level 12.06
2nd Support Level 11.76

See More

52-Week High 15.21
Fibonacci 61.8% 12.42
Last Price 12.37
Fibonacci 50% 11.56
Fibonacci 38.2% 10.70
52-Week Low 7.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar